Evaluation of miRNAs targeted RBPs under hypoxia in cancer

NISHANT CHAUDHARY

Tata Trust, Bombay House, Homi Mody Street, Mumbai, Maharashtra 400 001 India

Received: 30 July 2018; Accepted: 14 August 2018

Key words: Cancer, Hypoxia, miRNA, RNA binding Protein

On a global level, it has been observed that hypoxia significantly reduces total RNA levels and decreases total de novo translation. In the presence of hypoxia, wide range of responses have been observed due to RBPs. Some RBPs like HuR, PTBP, TTP, ERBP etc. have been shown to increase or decrease stability of their respective mRNA targets by binding to them. These target mRNAs are typically hypoxia-mediated targets like the master regulator of hypoxia, HIF-1 and its downstream targets involved in processes like cell signaling and angiogenesis (VEGF), metabolism (GLUT1) etc. (Gorospe et al. 2011). A stability inducing RBP associates with an mRNA and improves its half-life by preventing binding of degradation inducing RBPs and miRNAs (Zhao et al. 2000). Increase or decrease in translation rates of target mRNAs have also been observed as an indirect consequence of hypoxia through RBPs. RBPs can block translation by mobilizing miRNAs into p-bodies (like miRNAs) and RNA granules that form in response to hypoxia. In these structures, the mRNA is stable yet there is interaction with translation machinery (Gottschald et al. 2010). RBPs can also activate translation. In the presence of hypoxia, internal ribosome entry sites (IRESs) have been proposed to promoted translation. IRESs are cis acting elements present in some 5' UTRs that mediate ribosome recruitment. Under hypoxia, RBPs are shown to stabilize these IRESs thereby activating translation (Fähling 2009). ELAV (HuR) class of RNA binding proteins is involved in tandem with miRNAs when it comes to post transcriptional regulation. For example, in response to cellular stress, HuR is dephosphorylated and translocated, which relieves cationic amino acid transporter 1 (CAT1) mRNA from miR-122-mediated repression. HuR is also required for let-7-mediated repression of myc mRNA (Marike et al. 2011). It was also demonstrated that combination of HuR and mir-3134 promotes more stability of HuR targeted transcripts like SOX9, VEGFA and EFGR as compared to stability by HuR alone. The same study also found out that HuR also regulated about 80% of the genes regulated by miR-3134 (Marike et al. 2011). From these studies we can see that there is definitely some amount of interplay between RNA binding proteins involved in transcriptional regulation and micro RNAs.

Overall, it should be noted that although several trans-binding factors (RBPs and miRNAs) have been identified that modulate the expression of hypoxia-response genes in cultured cells, particularly in cancer cells, their interplay and its functional impact under hypoxic conditions in tissues, organs, and organisms remains largely unknown. Our work here identifies miRNAs that may play a major role in hypoxia signaling by regulation of levels of specific RBPs. Since target transcripts of both RBP and miRNAs are several cancer related genes, the perturbations in the RBP-miRNA interactions under hypoxia will most likely affect various hypoxia regulated cellular processes.

The cell lines used were U87MG (Glioblastomamulti-forme) and MCF7 (Breast cancer), which were obtained from NCCS, Pune. These cells were grown in DMEM (Invitrogen) with 10% FBS and 10,000 U/ml PenStrep.

RNA was extracted from the cells using Trizol method with the Fermentas® RNA Purification Kit. The purity and concentration of the RNA extracted was measured using Nanodrop and this RNA was stored at -80°C.

cDNA synthesis was performed using VersocDNA synthesis kit from Thermofisher®.

For plasmid transfection, 6 µl of lipofectamin was first added to 200 µl of Opti-MEM media. Side by side, 1.5 µg of plasmid and 200 µl of Opti-MEM media were added in another tube. These two tubes were mixed together in the order that the second mixture is added to the first after 5 min. Then this solution was kept for 20 min at room temperature. After 20 min, this mixture was added carefully in a drop-by-drop manner to the wells, along with DMEM. The cells were subsequently kept for 5 h and after this the media was changed.

SYBR® Green dye used to detect the quantity of cDNA (obtained from the miRNA or mRNA) in a given sample. This dye detected only when it is bound to double stranded DNA (dsDNA). As the amplification of the cDNA takes place, more of the dsDNA formed and consequently more SYBR® Green was detected. The number of cycles (Ct) required by a sample to reach a threshold value for detection of the dye is recorded. These were normalized against a housekeeping gene/miRNA to determine the fold change of the miRNA in the sample. This method was used to
quantify the miRNAs in the control and infected samples. MCF7 cells were grown separately under normoxia (21% O₂) and hypoxia (0.2% O₂) for 48 h and the levels of miR-210 and CPEB2 were determined using stem-loop qRT PCR and qRT PCR respectively (Fig. 1). We observed that miR-210 is upregulated and correspondingly CPEB2 is downregulated in hypoxia.

miR-210 overexpression construct (pB-210) and empty vector (pB) were transfected in MCF7 and U87MG and the levels of miR-210 and CPEB2 were determined using stem loop qRT-PCR or qRT-PCR respectively (Fig. 2). CPEB2 was downregulated in both U87MG and MCF7, on overexpression of miR-22.

We checked for the reported expression levels of miR-210 and CPEB2 in various cancers to look for inverse correlation of expression using StarBase software that integrates data from TCGA database. We found that while PTBP1 was uniformly over-expressed (Fig. 6). We observed that miR-193b was downregulated in both the cell lines while PTBP1 was downregulated in U87MG. Expression of PTBP1 in MCF7 could not be ascertained owing to RNA contamination.

miR-193b overexpression construct (pC-193b) or empty vector (pC) were transfected in MCF7 and U87MG and the levels of miR-193b were determined (Fig. 5). We observed that no overexpression of the miRNA in either U87MG or MCF7 cell lines took place and thus, we did not proceed to check for the levels of PTBP1.

We checked for the expression levels of miR-193b and PTBP1 in various cancers to look for inverse correlation of expression using StarBase software that integrates data from TCGA database. We found that while PTBP1 was uniformly over-expressed (Fig. 6). While several trans-binding factors (RBPs and miRNAs) have been recognized to change the expression of hypoxia-responsive genes in cultured cells, predominantly in cancer cells, their interaction and its functional impact under hypoxic conditions leftovers. Our work here is an attempt...
in this direction and suggests subsistence of interactions amid these two key classes of post-transcriptional regulators under normal or hypoxic conditions.

The combination of miRNA:RBP pairs used in this study yielded some interesting results. We studied two RBP:miRNA pairs, viz. CPEB2 – miR-210, PTBP1 – miR-193b. Interestingly, we found that CPEB family members (CPEB1 and CPEB2) are regulated by two hypoxia-regulated miRNAs. An inverse correlation of expression was also seen in miR-210-CPEB2 pair in various cancer patients with miR-210 overexpression and CPEB2 downregulation in preponderance of cancers. In our results, we also get a comparable result. On overexpressing miR-210, downregulation of CPEB2 was observed. An interesting facet into this study would be to look at the downstream targets of these RNA binding proteins. CPEB, for instance, regulates the myc mRNA which is associated with the cell cycle and apoptosis (Gorospe et al. 2011). Uncontrolled translation of the myc mRNA may cause the cell to bypass senescence and potentially enter a carcinogenic phase (Burns and Richter 2008). CPEB is also recognized to target p53, a tumour suppressor protein. It was reported that knockdown of CPEB resulted in ~50% decrease in p53 protein levels (Groisman 2002). Therefore, by regulating the CPEB mRNA through over expressing the miRNAs conferred in this study, we can foresee a means to manage CPEB and thereby may have power over the levels of myc and p53 mRNAs which could potentially influence the conversion of normal cell into a cancerous cell or succession of cancer. Subsequently, the discovery of first two miRNAs, lin-4 and let-7, perceptive of miRNAs in standard physiology and diseased circumstances, such as cancer (Orellana and Kasinski 2015) has highly developed. Progression in the field have been likely due to state-of-the-art technologies such as high throughput screening and deep sequencing, but chiefly due to the improvement of understanding appropriate in vivo model systems (Steinkraus et al. 2016). Therefore, various model systems that have been instrumental in elucidating the roles of miRNAs in cancers and the technologies that have been extensively applied to generate this animal model systems. Briefly, the utility of in vivo models in evaluating the potential of miRNAs as therapeutic agents or targets for treatment of various cancers will depend upon proper animal model.

SUMMARY

Micro RNAs (miRNAs) are miniature, non-coding RNA molecules which are implicated in post-transcriptional regulation of genes. RNA binding proteins (RBPs) are
involved in a diversity of functions including posttranscriptional regulation of genes. They have also been exposed to influence the messenger RNA stability by binding to their identified sequences at the 3’ untranslated region (UTR). Specific RBPs and miRNAs uncovered to be key participant in hypoxia signaling which is present in cancer cells, have been shown to involve in the outcome of the cell and drive towards tumor aggressiveness. Since both RBPs and miRNAs have been shown to be overstated by hypoxia and additionally significant since the site of battle of both players are the same (3’UTR of mRNA), we suggests that they might have role in tandem or be occupied in each other’s regulation. Stem loop qRT-PCR was used to check the expression levels of these target miRNAs and the corresponding RBPs in cancer cell lines, namely U87MG (Glioblastoma) and MCF7 (Breast cancer) under hypoxic and normoxic conditions. Transient over expression of the aforesaid miRNAs in the two cancer cell lines was examined using qRT-PCR to see the regulatory effects of these microRNAs on the corresponding target RBPs. Taken together, our results advocate that there could possibly be communication between the miRNA-RBP pairs that we had chosen and assessing the possibility as therapeutic agents for treatment of various cancers will depend upon suitable animal model.

REFERENCES
Burns D M and Richter J D. 2008. CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation. *Genes and Development* **22**: 3449–60.
Fähling M. 2009. Surviving hypoxia by modulation of mRNA translation rate. *Journal of Cellular and Molecular Medicine* **13**: 2770–79.
Gorospe M, Tominaga K, Wu X, Fähling M and Ivan M. 2011. Post-transcriptional control of the hypoxic response by RNA-binding proteins and microRNAs. *Frontiers in Molecular Neuroscience* **4**: 7.
Gottschald O R, Malec V, Krasteva G, Hasan D, Kamlah F, Herold S, Rose F, Seeger W and Hänze J. 2010. TIAR and TIA-1 mRNA binding proteins co-aggregate under conditions of rapid oxygen decline and extreme hypoxia and suppress the HIF-1a pathway. Journal of Molecular Cell Biology 2: 345–56.

Groisman I. 2002. Control of cellular senescence by CPEB. Cell 109: 473–83.

Marieke V K, Martijn K and Reuven A. 2011. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nature Reviews Cancer 11: 644–56.

Orellana E A and Kasinski A L. 2015. MicroRNAs in cancer: a historical perspective on the path from discovery to therapy. Cancers (Basel) 7(3): 1388–1405.

Steinkraus B R, Toegel M, Fulga T A 2016. Tiny giants of gene regulation: experimental strategies for microRNA functional studies. Wily Interdisciplinary Reviews Developmental Biology 5(3): 311–62.

Zhao Z, Chang F C and Furneaux H M. 2000. The identification of an endonuclease that cleaves within anHuR binding site in mRNA. Nucleic Acids Research 28: 2695–2701.